NCT02997228 2026-03-18
Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study
National Cancer Institute (NCI)
Phase 3 Active not recruiting
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Boehringer Ingelheim
National Cancer Institute (NCI)
Boehringer Ingelheim
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
University of Geneva, Switzerland
Alliance for Clinical Trials in Oncology
Bristol-Myers Squibb